Virus Removal and Eradication by Modified Double Filtration Plasmapheresis Decreases Factor XIII Levels
- 25 May 2010
- journal article
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 14 (3) , 287-291
Abstract
Factor XIII (FXIII) deficiency increases the chance for pathological bleeding, but this disorder cannot be detected by routine laboratory tests. Virus removal and eradication (VRAD, the trademark of Asahikasei Kuraray Medical) by double filtration plasmapheresis (DFPP) is an effective technique used to eradicate the hepatitis C virus in people afflicted with the disease. We have previously reported that DFPP significantly reduced FXIII in those undergoing this treatment. VRAD is a modified type of DFPP with a larger pore size of the second filter compared to conventional DFPP. Because VRAD may have similar effects on FXIII levels, we investigated the kinetics of FXIII during the course of VRAD therapy. A retrospective, observational study of the patients who underwent VRAD between July 2008 and May 2009 was performed. Reduction ratios and sieving coefficients of FXIII and other marker proteins were examined. FXIII levels were decreased to 20% after each therapy. The reduction ratio and sieving coefficients of FXIII were between those of IgG (0.4–0.5) and LDL cholesterol (0.35). Similar to other blood purification therapies, therapeutic intensity, molecular weight, and half life are crucial factors for solute removal. Although the coexistence of liver disease might modify the course of FXIII during VRAD, the therapy itself effectively reduced FXIII levels. FXIII levels should be closely monitored during VRAD in order to reduce the chance of negative clinical sequelae.Keywords
This publication has 9 references indexed in Scilit:
- Decreased Factor XIII Activity in a Patient With Subcutaneous Bleeding After Double Filtration PlasmapheresisTherapeutic Apheresis and Dialysis, 2009
- Double filtration plasmapheresis and interferon combination therapy for chronic hepatitis C patients with genotype 1 and high viral loadHepatology Research, 2007
- Double Filtration Plasmapheresis Can Decrease Factor XIII ActivityTherapeutic Apheresis and Dialysis, 2007
- Physiopathology and Regulation of Factor XIIIThrombosis and Haemostasis, 2001
- Factor XIII deficiency and postoperative hemorrhage after neurosurgical proceduresSurgical Neurology, 2000
- Blood Coagulation Factor XIIIThrombosis Research, 1999
- Factor XIII: Inherited and acquired deficiencyBlood Reviews, 1993
- COAGULATION FACTOR XIII A AND B SUBUNITS IN BONE MARROW AND LIVER TRANSPLANTATIONTransplantation, 1987
- The Half Life of Factor XIII in the Management of Inherited DeficiencyThrombosis and Haemostasis, 1983